Boston Scientific is a medical device manufacturer that specializes in cardiovascular, rhythm management and medical-surgical equipment. Meyer says Boston Scientific has an impressive pipeline of products in development and is well positioned in key markets in the long term. As a result, she says investors should forgive the company for recent missteps and focus on key growth drivers moving forward, including the Watchman FLX, Farapulse and ACURATE Neo2. Meyer projects Boston Scientific will outpace peers in earnings growth and deliver a higher return on invested capital in coming years. CFRA has a "buy" rating and $104 price target for BSX stock, which closed at $90.47 on Dec. 3.